The U.S. Food and Drug Administration (FDA) has lifted partial clinical holds placed on CA209 -039 (CheckMate -039) and CA204142, the phase 1 and 2 clinical trials investigating nivolumab-based combinations in patients with relapsed or refractory multiple myeloma, respectively.
The hold was initialliy placed on the trials in July, due to deaths in trials utilising pembrolizumab, another PD-1 inhibitor, in similar combinations.
The decision follows consultation with the FDA and agreement on amendments to the study protocols.
Patient enrollment for the following trials will resume in accordance with the amendments:
A third multiple myeloma trial, CA209 -602 (CheckMate -602), remains on partial clinical hold.
Bristol-Myers Squibb is continuing to work with the FDA to determine next steps for this trial.
The study is not enrolling new patients, however, patients who are experiencing clinical benefit are continuing to receive treatment.
Source: Bristol-Myers Squibb
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.